MODERNA DROPS FORECAST FOR ITS 2021 DELIVERIES

Moderna is scaling back expectations for the number of COVID- 19 vaccine deliveries it expects to make this year and the revenue it will record from them. Issues including longer delivery lead times for exports and a temporary impact from expanding the company’s capacity to fill vials with vaccine and package them for shipping, which may shift some deliveries to early 2022, the drugmaker said Thursday. The company now expects fullyear, 2021 product sales of between $ 15 billion and $ 18 billion.